The Metallomics, Metabolomics and Small Molecules Sections of the Systems Technologies Core is led by Dr. Jeffrey Enders.

Jeffrey Enders, PhD         919-515-3290

The Metallomics, Metabolomics and Small Molecules Sections within the Systems Technologies Core (STC) provide elemental analysis of metals as well as workflows for analyzing the low molecular weight complement of cells, tissues, or biological fluids.  Metabolomics makes it feasible to uniquely profile the biochemistry of an individual, or system, apart from, or in addition to, the genome and proteome.  The metabolomics profile includes signals for endogenous compounds, and exogenously derived components (e.g., metals, chemicals, and drugs), and can include study designs to examine metabolic flux. Metabolomics is used to determine the pattern of changes (and related metabolites) arising from disease, dysfunction, disorder, or from the therapeutic or adverse effects of xenobiotics. These studies can be conducted via various sample matrices (e.g., biofluids, environmental samples).



The Metallomics, Metabolomics and Small Molecules Sections can consult on and conduct various studies with CHHE members:

The Specific Aims of the Metabolomics Section within the STC are:

AIM 1. Provide guidance in study design.   To provide guidance in study design, sample collection, storage, processing, and analytical methods to best address the needs of a study.  In addition, the RCMRC will provide direction in appropriate data analysis, pathway mapping, and data integration approaches.

AIM 2. Provide expertise in broad-spectrum metabolomics and analysis of targeted analytes.   To conduct broad spectrum metabolomics and metallomics, and use targeted methods for the analysis of specific endogenous or exogenous compounds.

AIM 3. Provide expertise in data analysis and pathway mappingTo determine metabolite(s) that correspond with the phenotype under investigation, and will use specialized software for pathway mapping, and integrating disparate data streams.

Please contact Jeffrey Enders, PhD ( for consultation and questions.